Oxurion

Oxurion EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oxurion (OXUR.BR) as of Oct 15, 2026 is 524,000.00 EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -11.71 M EUR — a change of -104.47% (higher).

EBITDA

524,000.00EUR

YoY

-104.47%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oxurion is 2024 524,000.00 EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oxurion was 2023 -11.71 M EUR. It decreases by -104.47% higher compared to the previous year.

The Oxurion EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
27.10 M EUR
Jan 1, 2018
-35.61 M EUR
Jan 1, 2019
-32.51 M EUR
Jan 1, 2020
-27.39 M EUR
Jan 1, 2021
-26.69 M EUR
Jan 1, 2022
-21.59 M EUR
Jan 1, 2023
-11.71 M EUR
Jan 1, 2024
524,000.00 EUR
The Oxurion EBITDA history
YEAREBITDAYoY
524,000.00EUR-104.47%
-11.71 MEUR-45.75%
-21.59 MEUR-19.11%
-26.69 MEUR-2.54%
-27.39 MEUR-15.76%
-32.51 MEUR-8.72%
-35.61 MEUR-231.44%
27.10 MEUR-201.98%
-26.57 MEUR-14.10%
-30.93 MEUR-30.65%
-44.60 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oxurion Stock analysis

What does Oxurion do? Oxurion NV is a biotechnology company based in Heverlee, Belgium, operating within the healthcare sector. The company has 77 employees and went public on July 7, 2006. Oxurion focuses on developing and commercializing treatments for vitreoretinal diseases. Its lead product, JETREA (ocriplasmin), received U.S. Food and Drug Administration approval for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. The company collaborates with Alcon, a division of Novartis, for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including cases associated with macular holes of 400 microns or smaller, with launches in the United Kingdom and Germany. Oxurion is also researching anti-PIGF (Placental Growth Factor), known as TB-403, for potential use in ophthalmic and oncology treatments. The company maintains operations in Belgium, the United States, and Ireland, with its headquarters in Heverlee, Vlaams-Brabant. Oxurion's website is www.oxurion.com. Oxurion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oxurion stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oxurion is 524,000.00 EUR in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oxurion changed from -11.71 M EUR to 524,000.00 EUR, representing a -104.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Oxurion since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Oxurion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Oxurion

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Oxurion